GT
TGTX icon

Glenmede Trust’s TG Therapeutics TGTX Stock Holding History

Glenmede Trust’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,562
Closed -$184K – 1344
2022
Q4 		$184K Buy
+15,562
New +$113K ﹤0.01% 1111
2021
Q3 		– Sell
-9,721
Closed -$377K – 1331
2021
Q2 		$377K Sell
9,721
-417
-4% -$16.4K ﹤0.01% 962
2021
Q1 		$488K Buy
10,138
+178
+2% +$8.55K ﹤0.01% 853
2020
Q4 		$518K Buy
+9,960
New +$337K ﹤0.01% 833

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Glenmede Trust's TGTX Position: Q1 2023 in Review

Glenmede Trust sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 15,562 shares — an estimated $184K sold.

Glenmede Trust first reported a position in TGTX in Q4 2020 and held it in 4 quarters. The position peaked at $518K in Q4 2020. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Glenmede Trust reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Glenmede Trust sold 15,562 TG Therapeutics shares in Q1 2023, an estimated $184K.
  • Glenmede Trust first reported a position in TG Therapeutics in Q4 2020 and held it in 4 quarters.
  • Glenmede Trust's TG Therapeutics position peaked at $518K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Glenmede Trust's 13F filing for Q1 2023, filed 15 May 2023.